Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The company automating data transfer and integration to modern cloud analytics and AI platforms updated on trading for Q1 to the end March 2026.</li>
<li>In line with the previous outlook statement the Company has achieved positive cash flow for the quarter.</li>
<li>This is a significant milestone and represents the first reported period of positive cash generation in the Company's history and a key step towards sustainable cash generation. </li>
</ul>


The company automating data transfer and integration to modern cloud analytics and AI platforms updated on trading for Q1 to the end March 2026.
In line with the previous outlook statement the Company has achieved positive cash flow for the quarter.
This is a significant milestone and represents the first reported period of positive cash generation in the Company's history and a key step towards sustainable cash generation. 


<ul>
<li>Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports H1 to December 2025.</li>
<li>Reported revenue is 37% higher at £4.2m, with an EBITDA loss of £1.7m compared to an EBITDA loss of £1.9m due to continued investment in the overhead base to support future growth and contract execution.</li>
<li>The net cash is £3.7m against £1.9m last year and after a fund raising in October 2025 of £3.2m to accelerate US expansion and support execution of major contracts. </li>
</ul>


Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports H1 to December 2025.
Reported revenue is 37% higher at £4.2m, with an EBITDA loss of £1.7m compared to an EBITDA loss of £1.9m due to continued investment in the overhead base to support future growth and contract execution.
The net cash is £3.7m against £1.9m last year and after a fund raising in October 2025 of £3.2m to accelerate US expansion and support execution of major contracts. 


<ul>
<li>Active Energy Group 0.08p £2.98m (AEG.L) The Company engaged in renewable energy, engineering soils, and forestry management business announces that it has signed binding Heads of Terms in relation to the proposed acquisition of the Ghummud Site in Abu Dhabi, subject to the completion of customary due diligence.</li>
<li>The Asset comprises a 3.5 megavolt-ampere live grid connection with an active transformer and associated electrical infrastructure, providing approximately 2.975 megawatts of available load.</li>
<li>The Asset is non-operational and does not comprise revenue-generating activities. It consists solely of the energised grid connection and related electrical infrastructure and land.</li>
</ul>


Active Energy Group 0.08p £2.98m (AEG.L) The Company engaged in renewable energy, engineering soils, and forestry management business announces that it has signed binding Heads of Terms in relation to the proposed acquisition of the Ghummud Site in Abu Dhabi, subject to the completion of customary due diligence.
The Asset comprises a 3.5 megavolt-ampere live grid connection with an active transformer and associated electrical infrastructure, providing approximately 2.975 megawatts of available load.
The Asset is non-operational and does not comprise revenue-generating activities. It consists solely of the energised grid connection and related electrical infrastructure and land.


<ul>
<li>The gold and critical raw materials focused exploration and development Company confirmed the successful completion of the first stage of the commissioned mineralogical and scoping test work on the Rare Earth, Niobium, Tantalum and Zirconium mineralisation at the Aries Deposit, part of the Motzfeldt Critical Metals Project in south Greenland.</li>
<li>All the confirmed mineral species have established global extractive pathways, a key advantage for Motzfeldt.</li>
<li>The next test work phases will assess the most appropriate separation techniques for concentrating the key critical minerals.</li>
</ul>


The gold and critical raw materials focused exploration and development Company confirmed the successful completion of the first stage of the commissioned mineralogical and scoping test work on the Rare Earth, Niobium, Tantalum and Zirconium mineralisation at the Aries Deposit, part of the Motzfeldt Critical Metals Project in south Greenland.
All the confirmed mineral species have established global extractive pathways, a key advantage for Motzfeldt.
The next test work phases will assess the most appropriate separation techniques for concentrating the key critical minerals.


Hybridan Small Cap Feast: 16 February 2026

Tortilla Mexican Grill / Equity Bottom-Up

<ul>
<li>The high-growth operator with a portfolio of assets across key Colombian hydrocarbon basins provides an update on the operational activity at the Mateguafa Attic field on the Tapir Block in the Llanos Basin of Colombia where Arrow holds a 50% beneficial interest.</li>
<li>The well was put on production at a heavily restricted rate, 21/128 choke and 30 Hz pump frequency, of around 230 BOPD gross (115 BOPD net).</li>
<li>The oil quality is 31° API and there is a 78% water cut (completion fluid and formation water). </li>
</ul>


The high-growth operator with a portfolio of assets across key Colombian hydrocarbon basins provides an update on the operational activity at the Mateguafa Attic field on the Tapir Block in the Llanos Basin of Colombia where Arrow holds a 50% beneficial interest.
The well was put on production at a heavily restricted rate, 21/128 choke and 30 Hz pump frequency, of around 230 BOPD gross (115 BOPD net).
The oil quality is 31° API and there is a 78% water cut (completion fluid and formation water). 


Tortilla Mexican Grill PLC - Hybridan Small Cap Feast: 28 January 2026

United Kingdom

Physiomics is a data-driven consultancy that provides Model-Informed Drug Development (MIDD), Biostatistics, Statistical Programming, and Bioinformatics solutions to biopharmaceutical companies and research institutes. The company utilizes its proprietary Virtual Tumour technology platform to optimize the design of cancer clinical trials and predict the effects of treatments. Physiomics was founded in 2001 and is headquartered in Abingdon, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Physiomics (PYC LN)

Hybridan Small Cap Feast: 14 April 2026

The company automating data transfer and integration to modern cloud analytics and AI platforms updated on trading for Q1 to the end March 2026.

Hybridan

Hybridan Small Cap Feast: 17 March 2026

Abingdon Health 8.25p £20.71m (ABDX.L) The developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech reports...

Hybridan

Hybridan Small Cap Feast: 10 March 2026

The Asset comprises a 3.5 megavolt-ampere live grid connection with an active transformer and associated electrical infrastructure, providing...

Hybridan

Hybridan Small Cap Feast: 16 February 2026

The next test work phases will assess the most appropriate separation techniques for concentrating the key critical minerals.

Hybridan

Tortilla Mexican Grill PLC - Hybridan Small Cap Feast: 28 January 2026

The well was put on production at a heavily restricted rate, 21/128 choke and 30 Hz pump frequency, of around 230 BOPD gross (115 BOPD net).

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)